# A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

> **NCT01695044** · PHASE2 · COMPLETED · sponsor: **Progenics Pharmaceuticals, Inc.** · enrollment: 119 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** PSMA ADC

## Key facts

- **NCT ID:** NCT01695044
- **Lead sponsor:** Progenics Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-10
- **Final completion:** 2015-02
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2017-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01695044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01695044, "A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01695044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*